CTRI/2015/05/005827
Completed
未知
A randomized, single center, double blind, two-period, crossover glucose clamp study to test for bioequivalence between two recombinant human mixed insulins, Wockhardtâ??s Wosulin 30R/70N (regular insulin human, 30 IU per ml /isophane suspension 70 IU per ml) and Novolin® 70/30, in healthy subjects
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Wockhardt Limited
- Enrollment
- 56
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Considered generally healthy upon completion of medical history, physical examination X\-ray chest (PA view), ECG and biochemical investigations as judged by the Investigator.
- •2\.Body Mass Index (BMI) between 18\.0 and 27\.0 kg/m2, inclusive.
- •3\.Non\-smoker, defined as no nicotine consumption for last six months.
- •4\.Subjects who agreed for verbal and written consent to audio\-visual recording of the discussion of consent process and agreed to provide the signed and dated informed consent before any trial\-related activities. (Trial\-related activities are any procedure that would not have been performed during normal management of the subject.).
- •5\.Subjects with normal results of 2 hours Oral Glucose Tolerance Test (OGTT) performed at screening.
Exclusion Criteria
- •1\.Previous participation in this trial or other clinical trials within the last 90 days.
- •2\.Clinically significant abnormal haematology or biochemistry screening tests, as judged by the Investigator. In particular, subjects with elevated liver enzymes (AST or ALT 2 times the upper limit of normal) or impaired renal function (elevated serum creatinine values above the upper limit of normal)
- •3\.History/presence of disorder related to CVS, CNS, Respiratory tract, GIT, Endocrinology, Haematology, Immunological or any other systemic disorder including any serious systemic infectious disease, as judged by the Investigator.
- •4\.History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, gross anaemia (or subject with haemoglobin level 12 gm/dl at screening) or hemoglobinopathy will not be eligible to participate in the trial.
- •5\.History of alcohol or drug abuse in the past five years.
- •6\.Any positive test for drugs of abuse and /or alcohol at screening.
- •7\.Hepatitis B or C or HIV or VDRL positive.
- •8\.Use of prescription drugs within 3 weeks prior to screening.
- •9\.Use of non\-prescription drugs, except routine vitamins, within 2 weeks prior to screening.
- •10\.Mental incapacity, unwillingness or language barriers precluding adequate understanding or subject co\-operation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of a single intravenous dose of rifampicin on the pharmacokinetics of ACT-246475 in healthy subjects.NL-OMON46064Idorsia Pharmaceuticals Ltd14
Completed
Not Applicable
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of rifampicin on the pharmacokinetics of clazosentan in healthy male subjects.NL-OMON45870Idorsia Pharmaceuticals Ltd14
Completed
Not Applicable
Bio-equivalence study of Biphasic Insulin Aspart Injection (30/70)CTRI/2021/09/036601Wockhardt Bio AG14
Completed
Phase 1
Bio-equivalence study of Biphasic Insulin Aspart Injection (30/70)CTRI/2023/02/050076Wockhardt Bio AG56
Completed
Not Applicable
A single-center, randomized, double-blind, double-dummy, placebo- and active-controlled, 4-way cross-over study to assess next-day driving performance following single and multiple evening administrations of ACT-541468 in middle-aged and elderly subjects.NL-OMON48154Idorsia Pharaceuticals Ltd.56